Testicular Cancer Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 9 studies associated with Testicular Cancer .
Here is a small sampling of Testicular Cancer studies by title:
- Causal inference multiple imputation investigation of the impact of cannabinoids and other substances on ethnic differentials in US testicular cancer incidence
- Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management
- Cannabinoid Receptors Signaling in the Development, Epigenetics, and Tumours of Male Germ Cells
- Cannabis use and incidence of testicular cancer: a 42-year follow-up of Swedish men between 1970 and 2011
- Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis
Components of the Testicular Cancer Research Dashboard
- Dosing information available for Testicular Cancer
- Chemotype guidance for treating Testicular Cancer with cannabis
- Synopsis of cannabis research for Testicular Cancer
- Individual study details for Testicular Cancer
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Testicular Cancer
Description of Testicular Cancer
Testicular cancer formation begins in the testes inside the scrotum a loose and flexible bag of tissue underneath the penis. There are three unorthodox observations that can be made about testicular cancer. One, it is relatively rare two, it is the most common type of cancer affecting young males between the age of 15-35, and three it tends to responds well to orthodox treatments methodologies. Physiologically testicular cancer originates in germ cells (cells that produce sperm). There are two types, seminoma and non-seminoma. The difference is typically characterized by age of occurrence and aggressiveness. Non-seminoma testicular cancer tends to develop at a younger age and grow and spread more rapidly than the seminoma type.
Malignant neoplasm of testis
ICD-10 Code: C62
Testicular Cancer Symptoms:
Chronic presence of aches or pains in testis (may radiate to groin), lumps or swelling in or around the testis (usually one-sided), hormonal changes leading to enlarged breasts.
Also known as:
Malignant neoplasm of testis
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.